Dermata Therapeutics Inc. (DRMA)
NASDAQ: DRMA
· Real-Time Price · USD
0.71
-0.00 (-0.32%)
At close: Jun 16, 2025, 3:59 PM
0.70
-0.91%
Pre-market: Jun 17, 2025, 08:34 AM EDT
-0.32% (1D)
| Bid | 0.7 |
| Market Cap | 4.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.46M |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -0.69 |
| Analyst | Buy |
| Ask | 0.8 |
| Volume | 46,444 |
| Avg. Volume (20D) | 1,438,536 |
| Open | 0.70 |
| Previous Close | 0.71 |
| Day's Range | 0.70 - 0.71 |
| 52-Week Range | 0.66 - 5.00 |
| Beta | 0.57 |
About DRMA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRMA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+5.19%
Dermata shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
+19.01%
Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"
2 months ago · accessnewswire.com
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA...
3 months ago · accessnewswire.com
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinic...